7.20 Agents of Viral Hepatitis Flashcards Preview

Microbiology > 7.20 Agents of Viral Hepatitis > Flashcards

Flashcards in 7.20 Agents of Viral Hepatitis Deck (44)
Loading flashcards...
1

Infectious hepatitis

HAV

2

Serum hepatitis

HBV

3

Post-transfusion hepatitis

HCV

4

Enterically transmitted hepatitis

HEV

5

Picornaviridae
Icosahedral
ssRNA
Fecal oral

HAV

6

Autoclaving

HAV

7

Principal age distribution

Children
Young adults

8

Abrupt onset
Elevated IgM
No complication
Confers immunity

HAV

9

Detectable at onset of symptoms
Lifetime persistence

Anti-HAV

10

Indicates recent infection with HAV
4-6 months after infection

IgM anti-HAV

11

Gold standard for diagnosing hepatitis

HAV IgM

12

Highest rate of HAV incidence is between:

5-14

13

HAV immunity

2 doses

14

Hepadnaviridae
Spherical
dsDNA circular
Acid-sensitive
Chronic disease
Oncogenic

HBV

15

Made up exclusively of HBsAg

Spherical

16

Less frequently observed

Dane particles

17

Made up exclusively of HBsAg

Tubular or filamentous

18

Four phenotypes of HBsAg

adw (predominant), ayw, adr, ayr

19

Template for production of HBV mRNAs and RNA pre-genome

ccDNA

20

Predominant route of HBV infection

Parenteral

21

More extensive damage which prevents orderly liver cell regeneration

Acute viral hepatitis

22

Mild benign disease that may follow acute HBV infection

Persistent unresolved viral hepatitis

23

Histologic changes include inflammation and necrosis to collapse of the normal reticulum framework with bridging between portal triads or terminal hepatic veins

Chronic active hepatitis

24

Most useful detection methods for HB

ELISA for HBV Ag and Ab
PCR viral DNA

25

Occur early in the incubation period

DNA pol, HBV DNA, HBeAg

26

Associated with recovery from infection
Persists for more than 6 months in the presence of HBeAg

HBsAg

27

Detected at the onset of clinical illness
Indicative of viral replication

IgM-specific anti-HBc

28

Adults infected with HBV are at high risk of developing ____

HCC

29

First line therapies for HBV

Pegylated IFN alfa-2a
Entecavir
Tenofovir

30

Guanosine analogue inhibitor of HBV polymerase

Entecavir

31

Nucleotide analogue inhibitor of HBV reverse transcriptase and polymerase

Tenofovir

32

Second line therapies for HBV

Telbivudine

33

Cytosine nucleoside analogue
Inh of HBV DNA pol

Telbivudine

34

Third line therpay for HBV

Lamivudine
Adenofovir

35

Nucleoside analog viral polymerase inhibitors

Lamivudine
Adenofovir

36

Flaviviridae
Spherical
(+) stranded ssRNA
Chronic disease
Oncogenic

HCV

37

HCV treatment

Pegylated IFN + ribavirin

38

First generation protease inhibitor drugs
Target the viral protease, which cleaves the translated viral polypeptide into functional proteins

Telaprevir
Boceprevir

39

Second generation HCV antivirals

Sofosbuvir
Simepravir

40

Nucleotide analog HCV viral RNA inhibitor

Sofosbuvir

41

HCV protease inhibitor

Simepravir

42

Unclassified
Envelope- HBsAg
ssRNA, negative sense, circular
Parenteral
Smalles known human antigen
Not sexually transmitted

HDV

43

Only protein encoded for by HDV RNA

HDAg

44

Hepeviridae
ssRNA, positive sense
Not enveloped
Fecal-oral
Fulminant disease in pregnancy

HEV